Shanghai Henlius Biotech: First Chinese Patient Dosed for Phase 3 MRCT on ER+/HER2- Breast Cancer of HLX78

Source :: China Business News. December 24, 2024
Publication Year :: 2024
Abstract: Key Highlights: * Shanghai Henlius Biotech, Inc. dosed the first patient in China for Phase 3 clinical trial ELAINE-3 on ER+/HER2- breast cancer with HLX78 and abemaciclib * ELAINE-3 is [...]

Subjects :: Antineoplastic agents -- Product development
Biotechnology -- Genetic aspects
Clinical trials
Breast cancer -- Genetic aspects
Antimitotic agents -- Product development
Business
Business, international

Tools